Home > Insider Trading > Filing (0001209191-18-005361)

Filing Details

Accession Number:: 0001209191-18-005361
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-01-25 16:10:40
Reporting Period:: 2018-01-23

Accepted Time:: 2018-01-25 16:10:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1124140	Exact Sciences Corp	EXAS	Services-Commercial Physical & Biological Research (8731)	204782291

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1306119	T Kevin Conroy	C/O Exact Sciences Corp. 441 Charmany Drive Madison WI 53719	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-01-23	110,439	$0.83	940,491	No	4	M	Direct
Common Stock	Disposition	2018-01-23	12,077	$48.87	928,414	No	4	S	Direct
Common Stock	Disposition	2018-01-23	26,738	$49.54	901,676	No	4	S	Direct
Common Stock	Disposition	2018-01-23	41,588	$50.72	860,088	No	4	S	Direct
Common Stock	Disposition	2018-01-23	30,036	$51.66	830,052	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-01-23	110,439	$0.00	110,439	$0.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
265,002	2013-03-18	2019-03-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	25,000	Indirect	Held in 401(K) Account
Common Stock	65,189	Indirect	Held in Grantor Retained Annuity Trust

Footnotes

As previously announced by Exact Sciences Corporation in its Current Report on Form 8-K filed on August 11, 2017, the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017 which covers only the remaining portion of a stock option granted to Mr. Conroy in March 2009 that expires in March 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.15 to $49.145, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.155 to $50.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.17 to $52.09, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
In addition to the shares of Common Stock and options to purchase Common Stock reported on this Form 4, which total 1,185,243 shares, Mr. Conroy also holds, in the aggregate, an additional 1,125,158 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.